Literature DB >> 17393180

Islet cell transplantation today.

Reinhard G Bretzel1, Henning Jahr, Michael Eckhard, Isabel Martin, Daniel Winter, Mathias D Brendel.   

Abstract

INTRODUCTION: Long-term studies strongly suggest that tight control of blood glucose can prevent the development and retard the progression of chronic complications of type 1 diabetes mellitus. In contrast to conventional insulin treatment, replacement of a patient's islets of Langerhans either by pancreas organ transplantation or by isolated islet transplantation is the only treatment to achieve a constant normoglycemic state and avoiding hypoglycemic episodes, a typical adverse event of multiple daily insulin injections. However, the cost of this benefit is still the need for immunosuppressive treatment of the recipient with all its potential risks.
MATERIALS AND METHODS: Islet cell transplantation offers the advantage of being performed as a minimally invasive procedure in which islets can be perfused percutaneously into the liver via the portal vein. Between January 1990 and December 2004, 458 pancreatic islet transplants worldwide have been reported to the International Islet Transplant Registry (ITR) at our Third Medical Department, University of Giessen/Germany.
RESULTS: Data analysis of islet cell transplants performed in the last 5 years (1999-2004) shows at 1 year after adult islet transplantation a patient survival rate of 97%, a functioning islet graft in 82% of the cases, whereas insulin independence was meanwhile achieved in 43% of the cases. However, using a novel protocol established by the Edmonton Center/Canada, the insulin independence rates have improved significantly reaching meanwhile a 50-80% level.
CONCLUSION: Finally, the concept of islet cell or stem cell transplantation is most attractive, as it offers many perspectives: islet cell availability could become unlimited and islet or stem cells my be transplanted without life-long immunosuppressive treatment of the recipient, just to mention two of them.

Entities:  

Mesh:

Year:  2007        PMID: 17393180     DOI: 10.1007/s00423-007-0183-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  111 in total

1.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

Authors: 
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis.

Authors:  T Berney; R D Molano; P Cattan; A Pileggi; C Vizzardelli; R Oliver; C Ricordi; L Inverardi
Journal:  Transplantation       Date:  2001-01-15       Impact factor: 4.939

3.  Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.

Authors:  Axel Andres; Christian Toso; Philippe Morel; Sandrine Demuylder-Mischler; Domenico Bosco; Reto Baertschiger; Nadine Pernin; Pascal Bucher; Pietro E Majno; Leo H Bühler; Thierry Berney
Journal:  Transpl Int       Date:  2005-11       Impact factor: 3.782

4.  [Islet transplantation, stem cell transfer and regenerative therapy in diabetes mellitus].

Authors:  R G Bretzel; M Eckhard; H Jahr; M D Brendel
Journal:  Dtsch Med Wochenschr       Date:  2006-04-21       Impact factor: 0.628

5.  Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation.

Authors:  F Vargas; M Vives-Pi; N Somoza; P Armengol; L Alcalde; M Martí; M Costa; L Serradell; O Dominguez; J Fernández-Llamazares; J F Julian; A Sanmartí; R Pujol-Borrell
Journal:  Transplantation       Date:  1998-03-15       Impact factor: 4.939

6.  No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts.

Authors:  W Heneine; A Tibell; W M Switzer; P Sandstrom; G V Rosales; A Mathews; O Korsgren; L E Chapman; T M Folks; C G Groth
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

7.  Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  G L Warnock; N M Kneteman; E A Ryan; A Rabinovitch; R V Rajotte
Journal:  Diabetologia       Date:  1992-01       Impact factor: 10.122

8.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  The use of non-heart-beating donors for isolated pancreatic islet transplantation.

Authors:  James F Markmann; Shaoping Deng; Niraj M Desai; Xiaolun Huang; Ergun Velidedeoglu; Adam Frank; Chengyang Liu; Kenneth L Brayman; Moh Moh Lian; Bryan Wolf; Ewan Bell; Marko Vitamaniuk; Nicolai Doliba; Franz Matschinsky; Eileen Markmann; Clyde F Barker; Ali Naji
Journal:  Transplantation       Date:  2003-05-15       Impact factor: 4.939

10.  Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.

Authors:  Paola Maffi; Federico Bertuzzi; Francesca De Taddeo; Paola Magistretti; Rita Nano; Paolo Fiorina; Andrea Caumo; Paolo Pozzi; Carlo Socci; Massimo Venturini; Alessandro del Maschio; Antonio Secchi
Journal:  Diabetes Care       Date:  2007-01-26       Impact factor: 19.112

View more
  16 in total

1.  Gastric submucosa is inferior to the liver as transplant site for autologous islet transplantation in pancreatectomized diabetic Beagles.

Authors:  Zhu-Zeng Yin; Shu-Sen Wang; Qiang Li; Ying Huang; Li Chen; Gang Chen; Rong Liu; Xi-Mo Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

2.  Differentiation of Human Deceased Donor, Adipose-Derived, Mesenchymal Stem Cells into Functional Beta Cells.

Authors:  Prakash Rao; Dayanand Deo; Misty Marchioni
Journal:  J Stem Cells Regen Med       Date:  2020-12-11

Review 3.  Islet Microencapsulation: Strategies and Clinical Status in Diabetes.

Authors:  Mustafa Omami; James J McGarrigle; Mick Reedy; Douglas Isa; Sofia Ghani; Enza Marchese; Matthew A Bochenek; Maha Longi; Yuan Xing; Ira Joshi; Yong Wang; José Oberholzer
Journal:  Curr Diab Rep       Date:  2017-07       Impact factor: 4.810

4.  The immunosuppressive and protective ability of glucose-regulated protein 78 for improvement of alloimmunity in beta cell transplantation.

Authors:  M Wang; P Wang; Y Q Liu; J L Peng; X P Zhao; S Wu; F R He; X Wen; Y Li; G X Shen
Journal:  Clin Exp Immunol       Date:  2007-10-23       Impact factor: 4.330

5.  International workshop: islet transplantation without borders enabling islet transplantation in Greece with international collaboration and innovative technology.

Authors:  Klearchos K Papas; Theodore Karatzas; Thierry Berney; Thomas Minor; Paris Pappas; François Pattou; James Shaw; Christian Toso; Henk-Jan Schuurman
Journal:  Clin Transplant       Date:  2013-01-18       Impact factor: 2.863

6.  Current treatment options for chronic pancreatitis.

Authors:  Ayman M Abdel Aziz; Glen A Lehman
Journal:  Curr Treat Options Gastroenterol       Date:  2007-10

7.  Erythropoietin producing cells for potential cell therapy.

Authors:  Tamer Aboushwareb; Fernanda Egydio; Lauren Straker; Kenneth Gyabaah; Anthony Atala; James J Yoo
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

8.  Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1.

Authors:  Guiting Lin; Guifang Wang; Gang Liu; Li-Jun Yang; Lung-Ji Chang; Tom F Lue; Ching-Shwun Lin
Journal:  Stem Cells Dev       Date:  2009-12       Impact factor: 3.272

9.  Transplantation for type 1 diabetes mellitus. Whole organ or islets?

Authors:  D Vrochides; St Paraskevas; V Papanikolaou
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

10.  Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.

Authors:  Meidjie Ang; Christian Meyer; Mathias D Brendel; Reinhard G Bretzel; Thomas Linn
Journal:  Diabetologia       Date:  2013-12-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.